Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Bill Requires Standard Numerical Identifiers For Drug Tracking By 2010

Executive Summary

Legislation setting specific deadlines to implement drug tracking requirements was introduced April 17 by Reps. Steve Buyer, R-Ind., and Jim Matheson, D-Utah
Advertisement

Related Content

FDA To Unveil Drug Identifier System Soon, Short On Enforcement Authority
E-Pedigree Could Be A Key Law Enforcement Tool, J&J Exec Says
California E-Pedigree Phase-In Bill Moving Through State Legislature
RFID’s Possible Interaction With Biologics Queried By Biogen, Pfizer
Pharmacy groups oppose electronic pedigree bill
Counterfeiters Increasingly Target Chronic Illness - Reps. Buyer, Matheson
Foreign Drug Inspections Would Be Funded By Registration Fees In Draft Bill
FDA Begins Review Of E-Pedigree Options Just As California Delays Its Plan
FDA Begins Review Of E-Pedigree Options Just As California Delays Its Plan
Counterfeit Drugs, Food Safety Are Expected Focus Of New FDA Bill In House
Advertisement
UsernamePublicRestriction

Register

PS049530

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel